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Gary Tran, MD,* Daniel Parrinello, BS,† and Ishani Dalal, MD*
Abstract: Laparoscopic port-site metastasis from prostate cancer is a rare
complication after radical prostatectomy and pelvic lymph node dissection.
We report a case of port-site metastasis from prostate cancer identified on
18F-fluciclovine PET/CT for a patient with evidence of biochemical recur-
rence. Final pathology after targeted ultrasound and biopsy of the mass in
the right abdominal wall revealed prostatic adenocarcinoma.
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FIGURE 1. Noncontrast axial CT (A), fused axial 18F-fluciclovine PET/CT (B), noncontrast coronal CT (C), and fused coronal
18F-fluciclovine PET/CT (D). We report the case of a 70-year-old man with a history of prostate cancer status post radical
prostatectomy and radiation therapy. At the time of the 18F-fluciclovine PET/CT, his PSA value was 0.7 ng/mL. Increased
radiotracer uptake is visualized in the right anterior abdominal wall within the internal obliquemuscle, which is associated with
subtle asymmetric contour deformity on the noncontrast CT (arrows). No other areas of increased radiotracer uptake are
identified, including the prostatic bed. Differential considerations included benign lesion, malignant mesenchymal tumor, or
atypical prostatic metastasis. The case was discussed in the Genitourinary Tumor Board, and an ultrasound and a tissue sampling
were recommended.
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FIGURE 2. On ultrasound, there was a lobulated solid mass in the area of concern measuring 2.2  1.4  1.0 cm that
demonstrated internal vascularity. A biopsy was performed, and final pathology revealed prostatic adenocarcinoma.
Prostatic adenocarcinoma is the most common cancer inmales in the United States with over 174,000 estimated new cases and
over 76,000 estimated deaths in 2019.1 Laparoscopic radical prostatectomy has become increasingly more common due to
decreased rate of perioperative complications and quicker recovery times.2 Port-site metastasis is a rare but known complication
after laparoscopic urologic surgery ranging from 0.09% to 0.73%.3 Specifically, port-site metastasis from prostatic
adenocarcinoma has an even lower incidence with the first reported case documented by Larrousse et al4 in 2005. Many
mechanisms have been proposed including tumor spillage, direct inoculation, tumor aerosolization, and hematogenous
spread. Cases of port-site metastasis from prostatic adenocarcinoma have been described on PET/CT with the use
of 11C-choline, 18F-FDG, and 68Ga-prostate-specific membrane antigen.5–9 This case highlights the advantage of 18F-fluciclovine
PET/CT in evaluating suspected prostate cancer recurrence.
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